Central Aortic Blood Pressure Measurement Offers Deeper Insights to Support Research

More Data to Better Understand Cardiovascular Impact

Standard cardiovascular evaluation tools traditionally used in research have limited ability to characterize the hemodynamic effects of pharmacological or device-based interventions.

ATCOR’s noninvasive central aortic blood pressure waveform analysis and carotid-femoral PWV measurements directly assess aortic pressures and stiffness. These measurements bring value, confidence, and granularity to drug development and medical device interventions.


Get in touch with us


    Central Aortic Blood Pressure Measurement Offers Deeper Insights to Support Research
    More Data to Better Understand Cardiovascular Impact

    Standard cardiovascular evaluation tools traditionally used in research have limited ability to characterize the hemodynamic effects of pharmacological or device-based interventions.

    ATCOR’s noninvasive central aortic blood pressure waveform analysis and carotid-femoral PWV measurements directly assess aortic pressures and stiffness. These measurements bring value, confidence, and granularity to drug development and medical device interventions.


    Get in touch with us


      Advanced Hemodynamic Assessment Provides Greater Physiological Understanding

      Central hemodynamic assessments such as aortic pressure waveform analysis (PWA) and pulse wave velocity (PWV) measurement present offer a deeper understanding of the cardiovascular impact of disease and specific interventions. By characterizing ventricular-arterial interactions, pulse wave analysis can independently predict response to therapies, target organ damage, and risk of cardiovascular events. These critical insights significantly enhance investigators’ clinical program decision-making.

      Incorporating central arterial waveform analysis into your research allows you to:
      • Assess potential off-target benefits of novel interventions
      • Improve mechanistic understanding of interventions
      • Inform future cardiovascular outcome trials
      • Facilitate safety assessments

      Advanced Hemodynamic Assessment Provides Greater Physiological Understanding

      Central hemodynamic assessments such as aortic pressure waveform analysis (PWA) and pulse wave velocity (PWV) measurement present offer a deeper understanding of the cardiovascular impact of disease and specific interventions. By characterizing ventricular-arterial interactions, pulse wave analysis can independently predict response to therapies, target organ damage, and risk of cardiovascular events. These critical insights significantly enhance investigators’ clinical program decision-making.

      Incorporating central arterial waveform analysis into your research allows you to:
      • Assess potential off-target benefits of novel interventions
      • Improve mechanistic understanding of interventions
      • Inform future cardiovascular outcome trials
      • Facilitate safety assessments

      ATCOR’s SphygmoCor® technology has been used in research and pharmaceutical trials worldwide in a broad range of therapeutic areas, including hypertension, renal disease, heart failure, inflammatory processes, diabetes, men’s health, women’s health, and COPD.

      SphygmoCor® at a Glance

      All “Top 20 Hospitals” use SphygmoCor technology to measure central blood pressure (cBP)



      1,400+ studies using the SphygmoCor technology have been published in peer-reviewed clinical publications.


      8 out of Top 10 Pharma companies have used SphygmoCor technology in their clinical trials



      Over 11,000 patients have been tested with SphygmoCor technology in pharmaceutical trials



       

      Sign up to receive our email updates